BIOXCEL THERAPEUTICS INC (BTAI) Fundamental Analysis & Valuation

NASDAQ:BTAI • US09075P2048

Current stock price

1.08 USD
-0.02 (-1.82%)
At close:
1.09 USD
+0.01 (+0.93%)
After Hours:

This BTAI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BTAI Profitability Analysis

1.1 Basic Checks

  • BTAI had negative earnings in the past year.
  • BTAI had a negative operating cash flow in the past year.
  • In the past 5 years BTAI always reported negative net income.
  • BTAI had a negative operating cash flow in each of the past 5 years.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • BTAI's Return On Assets of -155.62% is on the low side compared to the rest of the industry. BTAI is outperformed by 84.72% of its industry peers.
Industry RankSector Rank
ROA -155.62%
ROE N/A
ROIC N/A
ROA(3y)-184.67%
ROA(5y)-135.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • BTAI has a better Gross Margin (74.45%) than 82.59% of its industry peers.
  • BTAI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for BTAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.72%
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BTAI Health Analysis

2.1 Basic Checks

  • BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BTAI has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BTAI has more shares outstanding
  • The debt/assets ratio for BTAI has been reduced compared to a year ago.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -26.27, we must say that BTAI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -26.27, BTAI is not doing good in the industry: 87.04% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.27
ROIC/WACCN/A
WACC8.8%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • BTAI has a Current Ratio of 0.83. This is a bad value and indicates that BTAI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BTAI's Current ratio of 0.83 is on the low side compared to the rest of the industry. BTAI is outperformed by 88.20% of its industry peers.
  • BTAI has a Quick Ratio of 0.83. This is a bad value and indicates that BTAI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.82, BTAI is not doing good in the industry: 88.01% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.82
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BTAI Growth Analysis

3.1 Past

  • BTAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.16%, which is quite impressive.
  • Looking at the last year, BTAI shows a very negative growth in Revenue. The Revenue has decreased by -71.67% in the last year.
  • Measured over the past years, BTAI shows a quite strong growth in Revenue. The Revenue has been growing by 19.10% on average per year.
EPS 1Y (TTM)74.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.75%
Revenue 1Y (TTM)-71.67%
Revenue growth 3Y19.1%
Revenue growth 5YN/A
Sales Q2Q%-30.05%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.30% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 272.73% on average over the next years. This is a very strong growth
EPS Next Y55.55%
EPS Next 2Y27.9%
EPS Next 3Y22.41%
EPS Next 5Y17.3%
Revenue Next Year162.23%
Revenue Next 2Y580.9%
Revenue Next 3Y345.68%
Revenue Next 5Y272.73%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. BTAI Valuation Analysis

4.1 Price/Earnings Ratio

  • BTAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • BTAI's earnings are expected to grow with 22.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.9%
EPS Next 3Y22.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BTAI Dividend Analysis

5.1 Amount

  • No dividends for BTAI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BTAI Fundamentals: All Metrics, Ratios and Statistics

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (4/9/2026, 8:14:55 PM)

After market: 1.09 +0.01 (+0.93%)

1.08

-0.02 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-11
Inst Owners17.47%
Inst Owner Change0%
Ins Owners2.05%
Ins Owner Change0.86%
Market Cap23.62M
Revenue(TTM)642.00K
Net Income(TTM)-69.90M
Analysts78.18
Price Target14.08 (1203.7%)
Short Float %13.4%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.66%
Min EPS beat(2)-81.51%
Max EPS beat(2)24.18%
EPS beat(4)2
Avg EPS beat(4)-2.21%
Min EPS beat(4)-81.51%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)15.95%
EPS beat(12)6
Avg EPS beat(12)8.54%
EPS beat(16)7
Avg EPS beat(16)3.6%
Revenue beat(2)1
Avg Revenue beat(2)0.07%
Min Revenue beat(2)-54.79%
Max Revenue beat(2)54.93%
Revenue beat(4)1
Avg Revenue beat(4)-28.55%
Min Revenue beat(4)-61.4%
Max Revenue beat(4)54.93%
Revenue beat(8)3
Avg Revenue beat(8)-22.73%
Revenue beat(12)3
Avg Revenue beat(12)-28.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.48%
PT rev (3m)-12.66%
EPS NQ rev (1m)4.85%
EPS NQ rev (3m)11.76%
EPS NY rev (1m)0%
EPS NY rev (3m)6.46%
Revenue NQ rev (1m)-19.54%
Revenue NQ rev (3m)-23.2%
Revenue NY rev (1m)-30.57%
Revenue NY rev (3m)-53.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.79
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.71
EYN/A
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)-2.63
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS0.03
BVpS-4.37
TBVpS-4.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.45%
FCFM N/A
ROA(3y)-184.67%
ROA(5y)-135.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.72%
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.82
Altman-Z -26.27
F-Score3
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.75%
EPS Next Y55.55%
EPS Next 2Y27.9%
EPS Next 3Y22.41%
EPS Next 5Y17.3%
Revenue 1Y (TTM)-71.67%
Revenue growth 3Y19.1%
Revenue growth 5YN/A
Sales Q2Q%-30.05%
Revenue Next Year162.23%
Revenue Next 2Y580.9%
Revenue Next 3Y345.68%
Revenue Next 5Y272.73%
EBIT growth 1Y22.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.39%
EBIT Next 3Y-1.07%
EBIT Next 5Y34.59%
FCF growth 1Y20.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.01%
OCF growth 3YN/A
OCF growth 5YN/A

BIOXCEL THERAPEUTICS INC / BTAI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to BTAI.


Can you provide the valuation status for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIOXCEL THERAPEUTICS INC (BTAI). This can be considered as Overvalued.


How profitable is BIOXCEL THERAPEUTICS INC (BTAI) stock?

BIOXCEL THERAPEUTICS INC (BTAI) has a profitability rating of 1 / 10.


How financially healthy is BIOXCEL THERAPEUTICS INC?

The financial health rating of BIOXCEL THERAPEUTICS INC (BTAI) is 0 / 10.